Head-to-Head drug showdown offers new hope for tough Crohn's cases
NCT ID NCT07149467
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 22 times
Summary
This study tests two medications, ustekinumab and upadacitinib, against each other in people with Crohn's disease that hasn't responded to standard treatments. About 454 adults who have failed at least one anti-TNF therapy will be randomly assigned to one of the two drugs. The goal is to see which drug works better at putting the disease into remission by week 16, helping doctors and patients choose the best option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE AGGRAVATED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.